American Capital Management Inc. Acquires Shares of 162,110 IDEXX Laboratories, Inc. $IDXX

Key Points

• American Capital Management initiated a 162,110-share position in IDEXX Laboratories valued at approximately $85.3 million, making the stock its sixth-largest holding and representing 3.8% of its portfolio.
• IDEXX reported quarterly EPS of $4.27, beating estimates of $3.94, while revenue rose 9.7% year over year to $1.22 billion. The company maintained fiscal 2026 guidance of $14.69–$14.94 in EPS.
• Analyst sentiment remains positive but cautious, with six Buy ratings and four Holds producing a “Moderate Buy” consensus and an average price target of $747, despite the stock trading near $553.44.

American Capital Management Inc. bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 162,110 shares of the company's stock, valued at approximately $85,341,000. IDEXX Laboratories makes up 3.8% of American Capital Management Inc.'s investment portfolio, making the stock its 6th largest holding. American Capital Management Inc. owned about 0.21% of IDEXX Laboratories at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. Elyxium Wealth LLC bought a new stake in IDEXX Laboratories during the fourth quarter worth $3,666,459,000. State Street Corp lifted its holdings in IDEXX Laboratories by 4.0% during the 4th quarter. State Street Corp now owns 3,656,626 shares of the company's stock worth $2,473,817,000 after buying an additional 138,956 shares during the period. J. Stern & Co. LLP lifted its position in shares of IDEXX Laboratories by 23,694.7% in the 4th quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company's stock worth $1,795,072,000 after purchasing an additional 2,642,200 shares during the period. Geode Capital Management LLC grew its holdings in IDEXX Laboratories by 3.5% during the 4th quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company's stock worth $1,749,380,000 after acquiring an additional 86,263 shares during the period. Finally, Invesco Ltd. increased its holdings in IDEXX Laboratories by 13.8% in the fourth quarter. Invesco Ltd. now owns 1,502,218 shares of the company's stock worth $1,016,296,000 after purchasing an additional 181,955 shares in the last quarter. Institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Trading Up 0.6%

Shares of IDXX stock opened at $553.44 on Thursday. The company's fifty day simple moving average is $559.49 and its two-hundred day simple moving average is $574.63. The stock has a market capitalization of $43.60 billion, a price-to-earnings ratio of 38.92, a PEG ratio of 2.94 and a beta of 1.54. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. IDEXX Laboratories, Inc. has a 1 year low of $518.55 and a 1 year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating analysts' consensus estimates of $3.94 by $0.33. The business had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The company's quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Weiss Ratings raised shares of IDEXX Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a research report on Wednesday, July 29th. Wall Street Zen cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Sunday, July 12th. UBS Group lifted their price target on IDEXX Laboratories from $620.00 to $670.00 and gave the company a "neutral" rating in a research note on Wednesday, August 5th. Citigroup increased their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 5th. Finally, Barclays dropped their target price on IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating on the stock in a report on Tuesday, August 11th. Six analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $747.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source